EMA Recommends Granting a Marketing Authorisation for Camizestrant By Ogkologos - June 5, 2026 14 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR New on NCI’s Websites for March 2022 March 16, 2022 Ivonescimab Plus Chemotherapy Significantly Improves PFS in Patients with NSCLC Previously... June 19, 2024 Workout Wednesday – Upper Body Stretches July 1, 2020 ESMO Highlights the Importance of Prioritising the Fight Against Cancer in... September 10, 2025 Load more HOT NEWS Ventana HER2 Dual ISH Assay, A New Diagnostic Tool From Roche,... Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia Population-based lung cancer screening can reduce mortality in people who have... Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities
